Ardelyx(ARDX.US)

Last Updated 19:00:00 ET

Ardelyx Stock Performance Chart

longbridge loading
Company Encyclopedia
View More
name
Ardelyx
ARDX.US
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc.
1.928 T
ARDX.USMarket value -Rank by Market Cap -/-

Financial Score

17/04/2026 Update
C
BiotechnologyIndustry
Industry Ranking114/393
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-36.21%E
    • Profit Margin-15.12%D
    • Gross Margin72.73%A
  • Growth ScoreB
    • Revenue YoY22.09%A
    • Net Profit YoY-57.40%D
    • Total Assets YoY15.11%B
    • Net Assets YoY-3.66%D
  • Cash ScoreB
    • Cash Flow Margin68.97%C
    • OCF YoY22.09%A
  • Operating ScoreB
    • Turnover0.87B
  • Debt ScoreD
    • Gearing Ratio66.72%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026 | ARDX Stock News

    StockTitan·
    US
    ARDX
    -0.32%
    US
    BIB
    -1.42%
    US
    VHT
    -0.77%
    StockTitan·
    US
    ARDX
    -0.32%
    US
    BIB
    -1.42%
    US
    VHT
    -0.77%

    Could Ardelyx’s New CMO Reframe ARDX’s Long-Term Nephrology Pipeline Strategy?

    Simplywall·
    US
    BBH
    -1.28%
    US
    XLV
    -0.79%
    US
    ARKG
    -0.33%
    Simplywall·
    US
    BBH
    -1.28%
    US
    XLV
    -0.79%
    US
    ARKG
    -0.33%

    Ardelyx President and CEO Sells 41,000 Shares for $243,000

    nasdaq·
    US
    BIB
    -1.42%
    US
    IXJ
    -0.89%
    US
    IBB
    -1.06%
    nasdaq·
    US
    BIB
    -1.42%
    US
    IXJ
    -0.89%
    US
    IBB
    -1.06%

    Insider Selling: Ardelyx (NASDAQ:ARDX) CEO Sells 41,666 Shares of Stock

    Market Beat·
    US
    FBT
    -1.26%
    US
    XBI
    -0.73%
    US
    BIB
    -1.42%
    Market Beat·
    US
    FBT
    -1.26%
    US
    XBI
    -0.73%
    US
    BIB
    -1.42%

    Ardelyx (ARDX) Valuation Check After Recent Share Price Weakness And Growth Expectations

    Simplywall·
    US
    XLV
    -0.79%
    US
    BBH
    -1.28%
    US
    FBT
    -1.26%
    Simplywall·
    US
    XLV
    -0.79%
    US
    BBH
    -1.28%
    US
    FBT
    -1.26%
    © 2026 Longbridge｜Disclaimer